The dopamine-serotonin relationship in clozapine response. 1993

S Szymanski, and J Lieberman, and S Pollack, and R Munne, and A Safferman, and J Kane, and M Kronig, and T Cooper
Hillside Hospital, Long Island Jewish Medical Center, Glen Oaks, NY 11004.

The effects of clozapine on the dopamine and serotonin systems may underlie its atypical pharmacologic and clinical profile. To examine this hypothesis, we measured dopamine and serotonin plasma and cerebrospinal (CSF) metabolites and the relationship of these values to treatment response in 19 neuroleptic refractory and intolerant schizophrenic patients. Only a small change in the CSF and plasma homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) levels was found. However, the pretreatment CSF HVA/5HIAA ratio and, to a lesser extent, the CSF HVA level predicted treatment response. These results suggest that the modest relationship between HVA and 5-HIAA and treatment response supports the involvement of both neurotransmitters in the pathophysiology of schizophrenia.

UI MeSH Term Description Entries
D008297 Male Males
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D003024 Clozapine A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent. Clozaril,Leponex
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D004409 Dyskinesia, Drug-Induced Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199) Dyskinesia, Medication-Induced,Medication-Induced Dyskinesia,Drug-Induced Dyskinesia,Drug-Induced Dyskinesias,Dyskinesia, Drug Induced,Dyskinesia, Medication Induced,Dyskinesias, Drug-Induced,Dyskinesias, Medication-Induced,Medication Induced Dyskinesia,Medication-Induced Dyskinesias
D005260 Female Females
D006719 Homovanillic Acid A 3-O-methyl ETHER of (3,4-dihydroxyphenyl)acetic acid. 3-Methoxy-4-Hydroxyphenylacetic Acid,4-Hydroxy-3-Methoxyphenylacetic Acid,3 Methoxy 4 Hydroxyphenylacetic Acid,4 Hydroxy 3 Methoxyphenylacetic Acid,Acid, 3-Methoxy-4-Hydroxyphenylacetic,Acid, 4-Hydroxy-3-Methoxyphenylacetic,Acid, Homovanillic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006897 Hydroxyindoleacetic Acid 5-HIAA,5-Hydroxy-3-Indoleacetic Acid,5-Hydroxyindolamine Acetic Acid,5 Hydroxy 3 Indoleacetic Acid,5 Hydroxyindolamine Acetic Acid,Acetic Acid, 5-Hydroxyindolamine,Acid, 5-Hydroxy-3-Indoleacetic,Acid, 5-Hydroxyindolamine Acetic,Acid, Hydroxyindoleacetic

Related Publications

S Szymanski, and J Lieberman, and S Pollack, and R Munne, and A Safferman, and J Kane, and M Kronig, and T Cooper
March 2000, Molecular psychiatry,
S Szymanski, and J Lieberman, and S Pollack, and R Munne, and A Safferman, and J Kane, and M Kronig, and T Cooper
May 1992, The British journal of psychiatry. Supplement,
S Szymanski, and J Lieberman, and S Pollack, and R Munne, and A Safferman, and J Kane, and M Kronig, and T Cooper
September 1978, European journal of pharmacology,
S Szymanski, and J Lieberman, and S Pollack, and R Munne, and A Safferman, and J Kane, and M Kronig, and T Cooper
January 1993, Lancet (London, England),
S Szymanski, and J Lieberman, and S Pollack, and R Munne, and A Safferman, and J Kane, and M Kronig, and T Cooper
September 1993, The American journal of psychiatry,
S Szymanski, and J Lieberman, and S Pollack, and R Munne, and A Safferman, and J Kane, and M Kronig, and T Cooper
February 1995, Neuroscience letters,
S Szymanski, and J Lieberman, and S Pollack, and R Munne, and A Safferman, and J Kane, and M Kronig, and T Cooper
January 1989, Psychopharmacology,
S Szymanski, and J Lieberman, and S Pollack, and R Munne, and A Safferman, and J Kane, and M Kronig, and T Cooper
March 1997, Canadian journal of psychiatry. Revue canadienne de psychiatrie,
S Szymanski, and J Lieberman, and S Pollack, and R Munne, and A Safferman, and J Kane, and M Kronig, and T Cooper
April 1999, Neuroreport,
S Szymanski, and J Lieberman, and S Pollack, and R Munne, and A Safferman, and J Kane, and M Kronig, and T Cooper
April 1984, Pharmacology, biochemistry, and behavior,
Copied contents to your clipboard!